The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation
British Journal of Pharmacology2013Vol. 171(9), pp. 2308–2320
Citations Over TimeTop 13% of 2013 papers
Matthew Skinner, Karen Philp, David Lengel, Lucy C. Coverley, Eva Lamm Bergström, Philip Glaves, Helen Musgrove, Helen Prior, Martin Braddock, R. Huby, Jon Curwen, Paul Duffy, Alexander R. Harmer
Abstract
Increased vascular resistance, secondary to reduced VEGF-induced NO release from endothelium, may contribute to BP increases observed with fostamatanib. This is consistent with the elevated BP induced by other drugs inhibiting VEGF signalling, although the contribution of other mechanisms cannot be excluded.
Related Papers
- → Assessment of endothelium-independent vasodilation(2018)42 cited
- → Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice(2019)26 cited
- → L-arginine as dietary supplement for improving microvascular function(2016)25 cited
- → Effects of fluvastatin on endothelium dependent vasodilatation function in elder hypertensives(2003)2 cited
- → SYK κινάση της τυροσίνης. Έκφραση και ρόλος της στον καρκίνο του μαστού(2005)